Spark Therapeutics Stock Price, News & Analysis (NASDAQ:ONCE)

$73.38 2.82 (4.00 %)
(As of 12/11/2017 06:00 AM ET)
Previous Close$70.56
Today's Range$70.79 - $74.18
52-Week Range$47.03 - $91.75
Volume669,500 shs
Average Volume398,833 shs
Market Capitalization$2.72 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics logoSpark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Receive ONCE News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ONCE
CUSIPN/A
Phone215-220-9300

Debt

Debt-to-Equity RatioN/A
Current Ratio15.80%
Quick Ratio15.80%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$20.18 million
Price / Sales134.58
Cash FlowN/A
Price / CashN/A
Book Value$10.73 per share
Price / Book6.84

Profitability

Trailing EPS($7.20)
Net Income$-123,650,000.00
Net Margins-1,090.11%
Return on Equity-60.01%
Return on Assets-53.26%

Miscellaneous

Employees213
Outstanding Shares37,010,000

Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics Inc (NASDAQ:ONCE) posted its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.79) by $0.11. The biotechnology company earned $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. Spark Therapeutics's quarterly revenue was up 45.8% on a year-over-year basis. During the same period in the prior year, the company posted ($1.07) EPS. View Spark Therapeutics' Earnings History.

Where is Spark Therapeutics' stock going? Where will Spark Therapeutics' stock price be in 2017?

17 Wall Street analysts have issued 1-year price targets for Spark Therapeutics' stock. Their predictions range from $28.00 to $111.00. On average, they expect Spark Therapeutics' share price to reach $91.50 in the next year. View Analyst Ratings for Spark Therapeutics.

What are Wall Street analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:

  • 1. Chardan Capital analysts commented, "We also see it as a important positive on Spark corporate governance that, e.g. during the panel, Spark provided caution to the panel attendees when panelists seemed interested in the potential for Luxturna re-treatment to further improve vision by treating more of the retina. (Spark noted that the company had not yet generated such data and responsibly urged caution.) After the unanimous backing of the panel, Luxturna, which has a PDUFA date of 12 January 2018, could achieve a number of firsts if approved, i.e." (10/13/2017)
  • 2. Cowen Inc analysts commented, "The FDA’s briefing documents appear mostly benign with most discussion centered." (10/10/2017)
  • 3. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (8/5/2017)
  • 4. Cantor Fitzgerald analysts commented, "2017 – Year of First Gene Therapy Approval in U.S.? Management reiterated its confidence in filing its rolling BLA in early 2017, and highlighted that the company has completed the necessary manufacturing runs to support its submission. Outstanding items for the filing include finalization of stability testing and CMC module write-up. We believe the timing of the filing could lead to the first approved gene therapy in the U.S. this year and remind investors that the FDA previously amended its granted orphan designation for voretigene neparvovec to cover inherited retinal diseases caused by biallelic RPE65 mutations." (2/23/2017)
  • 5. Stifel Nicolaus analysts commented, "Management's 4Q16 earnings announcement/call contained minimally-incremental insight on many of the data catalysts still anticipated for 1H17. We believe management's commentary around the current state of pre-commercialization activities for voretigene neparvovec (VN) ' including directionally positive feedback on both the access and reimbursement fronts ' should ameliorate some of the near-term concerns of those investors anticipating pricing/reimbursement to potentially represent a source of headline risk. We believe anticipation around a number of key near-term data catalysts ' including early-FY17 SPK-7001 data in choroideremia, updated early-April SPK-9001 data in hemophilia B, and preliminary mid-FY17 SPK-8011 data ' should keep ONCE shares at the forefront of relevancy over the coming months. Estimates largely unchanged." (2/23/2017)

Who are some of Spark Therapeutics' key competitors?

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:

  • Steven M. Altschuler M.D., Independent Chairman of the Board (Age 63)
  • Katherine A. High M.D., President, Chief Scientific Officer, Director (Age 65)
  • Jeffrey D. Marrazzo, Chief Executive Officer, Co-Founder, Director (Age 38)
  • Stephen W. Webster, Chief Financial Officer (Age 56)
  • John P Furey, Chief Operating Officer (Age 52)
  • Federico Mingozzi Ph.D., Chief Scientific Officer
  • Joseph W. La Barge Esq., General Counsel (Age 45)
  • Daniel R. Faga, Chief Business Officer (Age 37)
  • Lars G. Ekman M.D., Ph.D., Independent Director (Age 67)
  • Anand Mehra M.D., Independent Director (Age 41)

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Who owns Spark Therapeutics stock?

Spark Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (5.00%), Janus Henderson Group PLC (2.04%), Orbimed Advisors LLC (1.16%), Victory Capital Management Inc. (1.07%), Jennison Associates LLC (0.84%) and Ameriprise Financial Inc. (0.57%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics.

Who sold Spark Therapeutics stock? Who is selling Spark Therapeutics stock?

Spark Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Point72 Asset Management L.P., AXA, Essex Investment Management Co. LLC and Tocqueville Asset Management L.P.. Company insiders that have sold Spark Therapeutics company stock in the last year include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.

Who bought Spark Therapeutics stock? Who is buying Spark Therapeutics stock?

Spark Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Jennison Associates LLC, JPMorgan Chase & Co., Janus Henderson Group PLC, Perceptive Advisors LLC, Alyeska Investment Group L.P., Pictet Asset Management Ltd. and Russell Investments Group Ltd.. View Insider Buying and Selling for Spark Therapeutics.

How do I buy Spark Therapeutics stock?

Shares of Spark Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of Spark Therapeutics stock can currently be purchased for approximately $73.38.

How big of a company is Spark Therapeutics?

Spark Therapeutics has a market capitalization of $2.72 billion and generates $20.18 million in revenue each year. The biotechnology company earns $-123,650,000.00 in net income (profit) each year or ($7.20) on an earnings per share basis. Spark Therapeutics employs 213 workers across the globe.

How can I contact Spark Therapeutics?

Spark Therapeutics' mailing address is 3737 Market St Ste 1300, PHILADELPHIA, PA 19104-5543, United States. The biotechnology company can be reached via phone at 215-220-9300 or via email at [email protected]


MarketBeat Community Rating for Spark Therapeutics (ONCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  483
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Spark Therapeutics (NASDAQ:ONCE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.822.822.752.57
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $91.50$91.50$81.33$64.50
Price Target Upside: 29.68% upside14.68% upside0.67% downside7.20% upside

Spark Therapeutics (NASDAQ:ONCE) Consensus Price Target History

Price Target History for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ:ONCE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/7/2017Raymond James FinancialReiterated RatingBuyHighView Rating Details
11/15/2017BMO Capital MarketsReiterated RatingBuy$101.00N/AView Rating Details
11/8/2017Royal Bank Of CanadaLower Price TargetOutperform$100.00 -> $98.00N/AView Rating Details
10/16/2017SunTrust BanksSet Price TargetBuy$101.00N/AView Rating Details
10/13/2017BarclaysBoost Price TargetOverweight$104.00 -> $107.00N/AView Rating Details
10/13/2017Cantor FitzgeraldLower Price TargetBuy$105.00 -> $94.00N/AView Rating Details
10/13/2017Stifel NicolausReiterated RatingBuy -> Buy$92.00 -> $101.00N/AView Rating Details
10/13/2017Chardan CapitalReiterated RatingBuy$100.00N/AView Rating Details
10/10/2017CowenReiterated RatingBuy$95.00N/AView Rating Details
10/10/2017Jefferies GroupReiterated RatingBuy$95.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingBuy -> Buy$111.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$83.00HighView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageOutperform$87.00MediumView Rating Details
6/28/2017William BlairInitiated CoverageOutperform -> OutperformHighView Rating Details
5/10/2017WedbushReiterated RatingUnderperform$28.00MediumView Rating Details
2/22/2017J P Morgan Chase & CoSet Price TargetBuy$82.00N/AView Rating Details
2/9/2017Leerink SwannInitiated CoverageOutperform -> Outperform$85.00N/AView Rating Details
12/24/2015WunderlichDowngradeBuy -> HoldN/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Spark Therapeutics (NASDAQ:ONCE) Earnings History and Estimates Chart

Earnings by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ ONCE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($1.79)($1.90)$1.40 million$1.90 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.75)($1.89)$1.33 million$1.48 millionViewListenView Earnings Details
5/9/2017Q1 2017($1.36)($1.70)$1.35 million$1.27 millionViewListenView Earnings Details
2/22/2017Q416($1.12)($1.21)$1.32 million$16.30 millionViewListenView Earnings Details
11/3/2016Q316($1.01)($1.07)$1.26 million$1.30 millionViewN/AView Earnings Details
8/10/2016Q216($0.97)($1.04)$1.17 million$1.29 millionViewListenView Earnings Details
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details
3/9/2016Q415($0.73)($0.24)$1.30 million$17.20 millionViewListenView Earnings Details
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Spark Therapeutics (NASDAQ:ONCE) Earnings Estimates

2017 EPS Consensus Estimate: ($6.70)
2018 EPS Consensus Estimate: ($6.81)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.75)($1.32)($1.44)
Q2 20175($1.77)($1.71)($1.73)
Q3 20175($1.89)($1.64)($1.78)
Q4 20175($1.84)($1.63)($1.74)
Q1 20183($2.04)($1.88)($1.96)
Q2 20183($1.93)($1.47)($1.67)
Q3 20183($1.91)($1.21)($1.61)
Q4 20183($1.85)($1.25)($1.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Spark Therapeutics (NASDAQ:ONCE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Spark Therapeutics (NASDAQ ONCE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.30%
Institutional Ownership Percentage: 94.94%
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ ONCE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/28/2017Katherine A HighInsiderSell5,000$71.32$356,600.00View SEC Filing  
11/16/2017Stephen W WebsterCFOSell10,000$70.14$701,400.00View SEC Filing  
11/13/2017Barge Joseph LaInsiderSell5,500$71.44$392,920.00View SEC Filing  
11/13/2017Jeffrey D MarrazzoCEOSell20,000$71.54$1,430,800.00View SEC Filing  
11/9/2017Barge Joseph LaInsiderSell3,309$71.31$235,964.79View SEC Filing  
10/31/2017Katherine A HighInsiderSell5,000$83.30$416,500.00View SEC Filing  
10/24/2017Daniel FagaInsiderSell7,500$80.96$607,200.00View SEC Filing  
10/20/2017Daniel FagaInsiderSell6,000$79.95$479,700.00View SEC Filing  
9/26/2017Katherine A HighInsiderSell5,000$86.16$430,800.00View SEC Filing  
9/21/2017Hospital Of Philade Children'sDirectorSell1,000,000$84.63$84,630,000.00View SEC Filing  
9/19/2017Daniel FagaInsiderSell1,500$85.00$127,500.00View SEC Filing  
9/12/2017Daniel FagaInsiderSell6,000$82.50$495,000.00View SEC Filing  
9/7/2017Daniel FagaInsiderSell3,000$85.02$255,060.00View SEC Filing  
9/5/2017Barge Joseph LaInsiderSell5,500$81.00$445,500.00View SEC Filing  
8/29/2017Katherine A HighInsiderSell10,000$80.25$802,500.00View SEC Filing  
8/23/2017Jeffrey D MarrazzoCEOSell21,350$80.01$1,708,213.50View SEC Filing  
8/15/2017Stephen W WebsterCFOSell10,000$79.38$793,800.00View SEC Filing  
8/11/2017Jeffrey D MarrazzoCEOSell15,000$75.10$1,126,500.00View SEC Filing  
8/2/2017Jeffrey D MarrazzoCEOSell28,650$80.01$2,292,286.50View SEC Filing  
7/31/2017Stephen W WebsterCFOSell2,337$71.12$166,207.44View SEC Filing  
7/25/2017Katherine A HighInsiderSell10,000$72.53$725,300.00View SEC Filing  
7/24/2017Anand MehraDirectorSell211,858$70.15$14,861,838.70View SEC Filing  
7/24/2017Daniel FagaInsiderSell3,000$70.00$210,000.00View SEC Filing  
7/5/2017Jeffrey D MarrazzoCEOSell5,669$65.00$368,485.00View SEC Filing  
6/29/2017Daniel FagaInsiderSell4,500$62.71$282,195.00View SEC Filing  
6/27/2017Katherine A HighInsiderSell10,000$60.96$609,600.00View SEC Filing  
6/21/2017Anand MehraDirectorSell6,302$65.00$409,630.00View SEC Filing  
6/21/2017Jeffrey D MarrazzoCEOSell9,331$65.00$606,515.00View SEC Filing  
6/19/2017Katherine A HighInsiderSell10,000$60.00$600,000.00View SEC Filing  
6/19/2017Stephen W WebsterCFOSell7,663$60.00$459,780.00View SEC Filing  
6/7/2017Barge Joseph LaGeneral CounselSell5,000$55.00$275,000.00View SEC Filing  
4/25/2017Katherine A HighInsiderSell15,000$55.33$829,950.00View SEC Filing  
4/25/2017Stephen W WebsterCFOSell10,000$55.18$551,800.00View SEC Filing  
4/24/2017Katherine A HighInsiderSell2,060$55.01$113,320.60View SEC Filing  
4/24/2017Stephen W WebsterCFOSell1,898$55.00$104,390.00View SEC Filing  
4/3/2017Barge Joseph LaGeneral CounselSell5,000$52.73$263,650.00View SEC Filing  
3/1/2017Anand MehraDirectorSell84,654$65.02$5,504,203.08View SEC Filing  
3/1/2017Barge Joseph LaGeneral CounselSell5,000$64.41$322,050.00View SEC Filing  
2/28/2017Anand MehraDirectorSell25,274$65.02$1,643,315.48View SEC Filing  
2/27/2017Anand MehraDirectorSell41,910$65.02$2,724,988.20View SEC Filing  
2/16/2017Anand MehraDirectorSell35,347$65.03$2,298,615.41View SEC Filing  
2/7/2017Anand MehraDirectorSell25,334$65.06$1,648,230.04View SEC Filing  
12/16/2016Anand MehraDirectorSell349,656$53.46$18,692,609.76View SEC Filing  
12/15/2016Barge Joseph LaInsiderSell3,000$52.98$158,940.00View SEC Filing  
12/13/2016Anand MehraDirectorSell122,532$55.17$6,760,090.44View SEC Filing  
11/14/2016Katherine A HighInsiderSell10,000$60.30$603,000.00View SEC Filing  
10/17/2016Jeffrey D MarrazzoCEOSell5,000$54.66$273,300.00View SEC Filing  
10/3/2016Barge Joseph LaInsiderSell3,000$60.14$180,420.00View SEC Filing  
9/16/2016Jeffrey D MarrazzoCEOSell10,000$62.68$626,800.00View SEC Filing  
9/15/2016Katherine A HighInsiderSell10,000$60.37$603,700.00View SEC Filing  
8/16/2016Hospital Of Philade Children'sDirectorSell1,000,000$60.90$60,900,000.00View SEC Filing  
8/11/2016Anand MehraDirectorSell29,963$60.13$1,801,675.19View SEC Filing  
8/11/2016Jeffrey D MarrazzoCEOSell16,970$60.04$1,018,878.80View SEC Filing  
8/10/2016Katherine A HighInsiderSell1,890$60.00$113,400.00View SEC Filing  
8/8/2016Anand MehraDirectorSell100$60.47$6,047.00View SEC Filing  
8/8/2016Jeffrey D MarrazzoCEOSell900$60.24$54,216.00View SEC Filing  
8/8/2016Katherine A HighInsiderSell500$60.24$30,120.00View SEC Filing  
8/4/2016Anand MehraDirectorSell5,064$60.00$303,840.00View SEC Filing  
8/3/2016Jeffrey D MarrazzoCEOSell16,530$60.02$992,130.60View SEC Filing  
8/3/2016Katherine A HighInsiderSell17,610$60.02$1,056,952.20View SEC Filing  
8/1/2016Anand MehraDirectorSell22,665$60.03$1,360,579.95View SEC Filing  
8/1/2016Jeffrey D MarrazzoCEOSell12,348$60.03$741,250.44View SEC Filing  
8/1/2016Katherine A HighInsiderSell13,983$60.02$839,259.66View SEC Filing  
7/18/2016Jeffrey D MarrazzoCEOSell5,000$52.53$262,650.00View SEC Filing  
7/15/2016Coelho Rogerio VivaldiInsiderSell7,000$53.03$371,210.00View SEC Filing  
7/5/2016Barge Joseph LaInsiderSell3,000$52.24$156,720.00View SEC Filing  
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.00View SEC Filing  
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00View SEC Filing  
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00View SEC Filing  
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.00View SEC Filing  
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.00View SEC Filing  
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00View SEC Filing  
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.00View SEC Filing  
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.90View SEC Filing  
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.00View SEC Filing  
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00View SEC Filing  
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00View SEC Filing  
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00View SEC Filing  
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00View SEC Filing  
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00View SEC Filing  
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00View SEC Filing  
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.00View SEC Filing  
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.00View SEC Filing  
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.00View SEC Filing  
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Spark Therapeutics (NASDAQ ONCE) News Headlines

Source:
DateHeadline
Excitement Builds Around Gene Therapy Cures For HemophiliaExcitement Builds Around Gene Therapy Cures For Hemophilia
finance.yahoo.com - December 9 at 4:34 PM
Spark Therapeutics (ONCE) Earns "Buy" Rating from Raymond James FinancialSpark Therapeutics (ONCE) Earns "Buy" Rating from Raymond James Financial
www.americanbankingnews.com - December 8 at 6:08 PM
Spark Therapeutics (ONCE), Pfizer (PFE) Announce Publication in NEJM of ...Spark Therapeutics (ONCE), Pfizer (PFE) Announce Publication in NEJM of ...
www.streetinsider.com - December 8 at 10:18 AM
[$$] Lighting a Spark for Gene Therapy[$$] Lighting a Spark for Gene Therapy
finance.yahoo.com - December 7 at 4:52 PM
With new lease, Spark Therapeutics stays true to West Phila. rootsWith new lease, Spark Therapeutics stays true to West Phila. roots
finance.yahoo.com - December 7 at 4:52 PM
With new large lease, Spark Therapeutics stays true to West Philly rootsWith new large lease, Spark Therapeutics stays true to West Philly roots
www.bizjournals.com - December 7 at 10:43 AM
Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia BSpark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
finance.yahoo.com - December 7 at 10:43 AM
Gene-therapy approach to hemophilia finds success in study, Spark stock surgesGene-therapy approach to hemophilia finds success in study, Spark stock surges
finance.yahoo.com - December 7 at 10:43 AM
Spark Therapeutics Inc (ONCE): Financial Strength AnalysisSpark Therapeutics Inc (ONCE): Financial Strength Analysis
finance.yahoo.com - December 7 at 10:43 AM
Spark Therapeutics Trying To Close In On Key Technical MeasureSpark Therapeutics Trying To Close In On Key Technical Measure
finance.yahoo.com - December 6 at 10:35 AM
ETFs with exposure to Spark Therapeutics, Inc. : December 5, 2017ETFs with exposure to Spark Therapeutics, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 4:34 PM
Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical ... - GlobeNewswire (press release)Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical ... - GlobeNewswire (press release)
globenewswire.com - December 5 at 12:01 PM
Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical Trials at 59th American Society of Hematology Annual Meeting and ExpositionSpark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical Trials at 59th American Society of Hematology Annual Meeting and Exposition
finance.yahoo.com - December 5 at 12:01 PM
Spark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017Spark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 5:35 PM
Spark Therapeutics Inc (ONCE) Insider Katherine A. High Sells 5,000 SharesSpark Therapeutics Inc (ONCE) Insider Katherine A. High Sells 5,000 Shares
www.americanbankingnews.com - November 29 at 8:22 PM
Zacks: Brokerages Anticipate Spark Therapeutics Inc (ONCE) Will Post Quarterly Sales of $10.94 MillionZacks: Brokerages Anticipate Spark Therapeutics Inc (ONCE) Will Post Quarterly Sales of $10.94 Million
www.americanbankingnews.com - November 29 at 9:58 AM
$10.94 Million in Sales Expected for Spark Therapeutics Inc (ONCE) This Quarter$10.94 Million in Sales Expected for Spark Therapeutics Inc (ONCE) This Quarter
www.americanbankingnews.com - November 29 at 6:50 AM
Zacks: Analysts Anticipate Spark Therapeutics Inc (ONCE) to Announce -$1.76 EPSZacks: Analysts Anticipate Spark Therapeutics Inc (ONCE) to Announce -$1.76 EPS
www.americanbankingnews.com - November 27 at 9:32 AM
Spark Therapeutics Inc (ONCE) Expected to Post Earnings of -$1.76 Per ShareSpark Therapeutics Inc (ONCE) Expected to Post Earnings of -$1.76 Per Share
www.americanbankingnews.com - November 27 at 9:14 AM
Spark Therapeutics Inc (ONCE) Stock Rating Lowered by ValuEngineSpark Therapeutics Inc (ONCE) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - November 26 at 9:00 AM
Spark Therapeutics, Inc. (ONCE) CFO Sells $701,400.00 in StockSpark Therapeutics, Inc. (ONCE) CFO Sells $701,400.00 in Stock
www.americanbankingnews.com - November 20 at 7:38 PM
$1 million price tag in spotlight as gene therapy becomes reality$1 million price tag in spotlight as gene therapy becomes reality
finance.yahoo.com - November 18 at 10:34 AM
Spark Therapeutics, Inc. (ONCE) Receives Consensus Recommendation of "Buy" from AnalystsSpark Therapeutics, Inc. (ONCE) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 16 at 2:10 PM
BMO Capital Markets Reiterates Buy Rating for Spark Therapeutics, Inc. (ONCE)BMO Capital Markets Reiterates Buy Rating for Spark Therapeutics, Inc. (ONCE)
www.americanbankingnews.com - November 15 at 11:36 PM
Oversold Conditions For Spark Therapeutics (ONCE) - NasdaqOversold Conditions For Spark Therapeutics (ONCE) - Nasdaq
www.nasdaq.com - November 15 at 7:06 AM
Barge Joseph La Sells 3,309 Shares of Spark Therapeutics, Inc. (ONCE) StockBarge Joseph La Sells 3,309 Shares of Spark Therapeutics, Inc. (ONCE) Stock
www.americanbankingnews.com - November 13 at 7:54 PM
Barge Joseph La Sells 5,500 Shares of Spark Therapeutics, Inc. (ONCE) StockBarge Joseph La Sells 5,500 Shares of Spark Therapeutics, Inc. (ONCE) Stock
www.americanbankingnews.com - November 13 at 7:28 PM
Spark Therapeutics, Inc. (ONCE) CEO Sells $1,430,800.00 in StockSpark Therapeutics, Inc. (ONCE) CEO Sells $1,430,800.00 in Stock
www.americanbankingnews.com - November 13 at 7:26 PM
Wedbush Weighs in on Spark Therapeutics, Inc.s Q4 2017 Earnings (ONCE)Wedbush Weighs in on Spark Therapeutics, Inc.'s Q4 2017 Earnings (ONCE)
www.americanbankingnews.com - November 13 at 4:50 AM
Three-year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational LUXTURNA™ (voretigene neparvovec) in Patients with Biallelic RPE65-mediated Inherited Retinal DiseaseThree-year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational LUXTURNA™ (voretigene neparvovec) in Patients with Biallelic RPE65-mediated Inherited Retinal Disease
finance.yahoo.com - November 10 at 8:35 PM
FY2017 Earnings Forecast for Spark Therapeutics, Inc. Issued By Jefferies Group (ONCE)FY2017 Earnings Forecast for Spark Therapeutics, Inc. Issued By Jefferies Group (ONCE)
www.americanbankingnews.com - November 10 at 2:28 PM
Spark Therapeutics, Inc. (ONCE) to Post FY2017 Earnings of ($7.86) Per Share, SunTrust Banks ForecastsSpark Therapeutics, Inc. (ONCE) to Post FY2017 Earnings of ($7.86) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - November 10 at 2:28 PM
FY2017 Earnings Forecast for Spark Therapeutics, Inc. (ONCE) Issued By Leerink SwannFY2017 Earnings Forecast for Spark Therapeutics, Inc. (ONCE) Issued By Leerink Swann
www.americanbankingnews.com - November 10 at 2:28 PM
FY2017 EPS Estimates for Spark Therapeutics, Inc. Lifted by William Blair (ONCE)FY2017 EPS Estimates for Spark Therapeutics, Inc. Lifted by William Blair (ONCE)
www.americanbankingnews.com - November 10 at 1:59 PM
Spark, Pfizer amend agreement for experimental hemophilia gene therapySpark, Pfizer amend agreement for experimental hemophilia gene therapy
finance.yahoo.com - November 9 at 8:19 PM
Here's Why Spark Therapeutics, Inc. Fell 9.3% in OctoberHere's Why Spark Therapeutics, Inc. Fell 9.3% in October
finance.yahoo.com - November 9 at 8:19 PM
Edited Transcript of ONCE earnings conference call or presentation 7-Nov-17 1:30pm GMTEdited Transcript of ONCE earnings conference call or presentation 7-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 8:19 PM
Spark Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ONCE-US : November 8, 2017Spark Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ONCE-US : November 8, 2017
finance.yahoo.com - November 9 at 8:19 PM
Spark Therapeutics, Inc. to Post Q1 2018 Earnings of ($1.88) Per Share, Jefferies Group Forecasts (ONCE)Spark Therapeutics, Inc. to Post Q1 2018 Earnings of ($1.88) Per Share, Jefferies Group Forecasts (ONCE)
www.americanbankingnews.com - November 9 at 11:43 AM
Spark Therapeutics (ONCE) CEO Jeff Marrazzo on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaSpark Therapeutics' (ONCE) CEO Jeff Marrazzo on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 9 at 10:06 AM
Heres Why Spark Therapeutics, Inc. Fell 9.3% in October - Motley FoolHere's Why Spark Therapeutics, Inc. Fell 9.3% in October - Motley Fool
www.fool.com - November 9 at 10:06 AM
Today’s Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Spark TherapeuticsToday’s Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Spark Therapeutics
finance.yahoo.com - November 9 at 10:06 AM
Zacks: Brokerages Anticipate Spark Therapeutics, Inc. (ONCE) Will Post Earnings of -$1.81 Per ShareZacks: Brokerages Anticipate Spark Therapeutics, Inc. (ONCE) Will Post Earnings of -$1.81 Per Share
www.americanbankingnews.com - November 8 at 9:32 PM
Spark Therapeutics, Inc. (ONCE) Announces Quarterly  Earnings ResultsSpark Therapeutics, Inc. (ONCE) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 8 at 4:44 PM
Heres Why Spark Therapeutics, Inc. Fell 9.3% in OctoberHere's Why Spark Therapeutics, Inc. Fell 9.3% in October
www.fool.com - November 7 at 2:41 PM
Spark Therapeutics, Inc. to Host Earnings CallSpark Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 8:16 AM
Spark Therapeutics, Inc. to Host Earnings CallSpark Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 8:15 AM
Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia BSpark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B
finance.yahoo.com - November 7 at 8:15 AM
Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business ProgressSpark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress
finance.yahoo.com - November 7 at 8:15 AM
Spark Therapeutics reports 3Q lossSpark Therapeutics reports 3Q loss
finance.yahoo.com - November 7 at 8:15 AM

SEC Filings

Spark Therapeutics (NASDAQ:ONCE) SEC Filings

DateFilerForm TypeView
12/04/2017
9:17 AM
Spark Therapeutics (Filer)
Form CT ORDER
View Filing
12/04/2017
9:05 AM
Spark Therapeutics (Filer)
Form CT ORDER
View Filing
11/29/2017
4:08 PM
High Katherine A (Reporting)
Spark Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing

Social Media

Financials

Spark Therapeutics (NASDAQ:ONCE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Spark Therapeutics (NASDAQ ONCE) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.